Relmada says independent analysis shows depression treatment unlikely to meet main trial goal-December 2024-www.financetom.com

Relmada says independent analysis shows depression treatment unlikely to meet main trial goal

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Relmada says independent analysis shows depression treatment unlikely to meet main trial goal

Dec 4, 2024 5:02 AM

Dec 4 (Reuters) - Relmada Therapeutics ( RLMD ) said on

Wednesday its treatment for a major depressive disorder is

"unlikely" to meet the main goal of a late-stage trial,

according to an independent data monitoring committee's

analysis.

(Reporting by Christy Santhosh in Bengaluru)

Previous page： Select Water Solutions Q3 revenue beats expectations Next page： Live Nation posts higher third-quarter revenue on strong fan demand

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Select Water Solutions Q3 revenue beats expectations

Nov 4, 2025

Overview * Select Water Solutions ( WTTR ) Q3 revenue beats analyst expectations despite sequential decline * Adjusted EBITDA for Q3 exceeds analyst estimates, indicating operational resilience * Company announces strategic infrastructure expansions in Permian Basin for future growth Outlook * Company expects Q4 2025 Water Infrastructure growth of approximately 10% * Select anticipates over 20% Water Infrastructure growth in...

Live Nation posts higher third-quarter revenue on strong fan demand

Nov 4, 2025

(Reuters) -Ticketmaster-parent Live Nation reported a rise in third-quarter revenue on Tuesday, helped by demand for concerts and festivals. Fans are spending on immersive live entertainment despite economic headwinds, benefiting Live Nation, which is a bellwether for discretionary spending across the entertainment industry. Strong fan demand drove another record quarter, as we continue to attract more fans to more shows...

Aflac Q3 Adjusted Earnings, Revenue Increase; Quarterly Dividend Maintained

Nov 4, 2025

04:26 PM EST, 11/04/2025 (MT Newswires) -- Aflac ( AFL ) reported Q3 adjusted earnings late Tuesday of $2.49 per diluted share, up from $2.16 a year earlier. Analysts polled by FactSet expected $1.77. Revenue for the quarter ended Sept. 30 was $4.74 billion, up from $2.95 billion a year earlier. Analysts expected $4.37 billion. The company maintained its quarterly...

Angi Q3 revenue misses expectations

Nov 4, 2025

Overview * Angi ( ANGI ) Q3 revenue fell 10% yr/yr, missing analyst expectations * Operating income for Q3 grew 179% yr/yr, driven by lower expenses * Adjusted EBITDA for Q3 beats analyst estimates, reflecting improved profitability Outlook * Company did not provide specific guidance for future quarters in its press release Result Drivers * PROPRIETARY GROWTH - Proprietary Service...